[1]
|
McDermott, M. (2020) Hyperthyroidism. Annals of Internal Medicine, 172, ITC49-ITC64.
https://doi.org/10.7326/AITC202004070
|
[2]
|
刘超, 蒋琳. 抗甲状腺药物不良反应的再认识[J]. 中华内分泌代谢杂志, 2011, 27(6): 529-532.
|
[3]
|
王宁, 王薇, 张红, 袁振芳, 郭晓蕙, 张俊清. 抗甲状腺药物与甲状腺功能亢进症所致肝功能异常的临床分析[J]. 中国临床药理学杂志, 2018, 34(3): 244-247.
|
[4]
|
Woeber, K. (2002) Me-thimazole-Induced Hepatotoxicity. Endocrine Practice, 8, 222-224.
https://doi.org/10.4158/EP.8.3.222
|
[5]
|
Heidari, R., Babaei, H. and Eghbal, M. (2013) Mechanisms of Methima-zole Cytotoxicity in Isolated Rat Hepatocytes. Drug and Chemical Toxicology, 36, 403-411. https://doi.org/10.3109/01480545.2012.749272
|
[6]
|
巩政, 王旗. 黄素单加氧酶3的基因多态性及其在药物代谢和毒性中的作用[J]. 中国中药杂志, 2015, 40(14): 2701-2705.
|
[7]
|
Heidari, R., Niknahad, H., Jamshidzadeh, A., Eghbal, M.A. and Abdoli. N. (2015) An Overview on the Proposed Mechanisms of Antithyroid Drugs-Induced Liver Injury. Advanced Pharmaceutical Bulletin, 5, 1-11.
https://doi.org/10.5681/apb.2015.001
|
[8]
|
殷静, 王芳, 王永艳, 汤洪策, 孙纯, 阎胜利. 甲巯咪唑致肝损害与黄素单加氧酶3E308G位点基因多态性的相关性研究[J]. 中国药学杂志, 2014. 49(15): 1338-1341.
|
[9]
|
Li, X., Yang, J., Jin, S., Dai, Y., Fan, Y., Fan, X., et al. (2020) Mechanistic Examination of Methimazole-Induced Hepatotoxi-city in Patients with Grave’s Disease: A Metabolomic Approach. Archives of Toxicology, 94, 231-244.
https://doi.org/10.1007/s00204-019-02618-z
|
[10]
|
Heidari, R., Niknahad, H., Jamshidzadeh, A. and Abdoli, N. (2014) Factors Affecting Drug-Induced Liver Injury: Antithyroid Drugs as Instances. Clinical and Molecular Hepatolo-gy, 20, 237-248.
https://doi.org/10.3350/cmh.2014.20.3.237
|
[11]
|
Lang, C., Meier, Y., Stieger, B., Beuers, U., Lang, T., Kerb, R., et al. (2007) Mutations and Polymorphisms in the Bile Salt Export Pump and the Multidrug Resistance Protein 3 Associat-ed with Drug-Induced Liver Injury. Pharmacogenet Genomics, 17, 47-60. https://doi.org/10.1097/01.fpc.0000230418.28091.76
|
[12]
|
Choi, J.H., Ahn, B.M., Yi, J., Lee, J.H., Lee, J.H., Nam, S.W., et al. (2007) MRP2 haplotypes Confer Differential Susceptibility to Toxic Liver Injury. Pharmacogenetics and Genomics, 17, 403-415.
https://doi.org/10.1097/01.fpc.0000236337.41799.b3
|
[13]
|
Li, L.M., Chen, L., Deng, G.H., Tan, W.T., Dan, Y.J., Wang, R.Q., et al. (2012) SLCO1B1 *15 Haplotype Is Associated with Rifampin-Induced Liver Injury. Molecular Med-icine Reports, 6, 75-82.
https://doi.org/10.3892/mmr.2012.900
|
[14]
|
Jin, S., Li, X., Fan, Y., Fan, X., Dai, Y., Lin, H., et al. (2019) Associ-ation between Genetic Polymorphisms of SLCO1B1 and Susceptibility to Methimazole-Induced Liver Injury. Basic & Clinical Pharmacology & Toxicology, 125, 508-517.
https://doi.org/10.1111/bcpt.13284
|
[15]
|
Stephens, C. and Andrade, R.J. (2020) Genetic Predisposition to Drug-Induced Liver Injury. Clinics in Liver Disease, 24, 11-23. https://doi.org/10.1016/j.cld.2019.08.003
|
[16]
|
Grove, J. and Aithal, G. (2015) Human Leukocyte Antigen Genetic Risk Factors of Drug-Induced Liver Toxicology. Expert Opinion on Drug Metabolism & Toxicology, 11, 395-409. https://doi.org/10.1517/17425255.2015.992414
|
[17]
|
Fan, W., Shiao, M.S., Hui, R.C., Su, S.C., Wang, C.W., Chang, Y.C., et al. (2017) HLA Association with Drug-Induced Adverse Reactions. Journal of Immunology Research, 2017, Article ID: 3186328.
https://doi.org/10.1155/2017/3186328
|
[18]
|
Ma, Q., Yang, W., Wang, L., Ma, L., Jing, Y., Wang, J., et al. (2020) Research Advances in the Association of Drug- Induced Liver Injury with Polymorphisms in Human Leukocyte Antigen. International Immunopharmacology, 81, Article ID: 106037. https://doi.org/10.1016/j.intimp.2019.106037
|
[19]
|
Petros, Z., Kishikawa, J., Makonnen, E., Yimer, G., Habtewold, A. and Aklillu, E. (2017) HLA-B* 57 Allele Is Associated with Concomitant Anti-Tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians. Frontiers in Pharmacology, 8, Article No. 90. https://doi.org/10.3389/fphar.2017.00090
|
[20]
|
Li, C., Rao, T., Chen, X., Zou, Z., Wei, A., Tang, J., et al. (2019) HLA-B* 35:01 Allele Is a Potential Biomarker for Predicting Polygonum multiflorum-Induced Liver Injury in Humans. Hepatology, 70, 346-357.
https://doi.org/10.1002/hep.30660
|
[21]
|
Nicoletti, P., Aithal, G.P., Chamberlain, T.C., Coulthard, S., Alshabeeb, M., Grove, J.I., et al. (2019) Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte An-tigen Alleles. Clinical Pharmacology and Therapeutics, 106, 245-253. https://doi.org/10.1002/cpt.1375
|
[22]
|
Fon-tana, R., Cirulli, E.T., Gu, J., Kleiner, D., Ostrov, D., Phillips, E., Schutte, R., et al. (2018) The Role of HLA-A*33:01 in Patients with Cholestatic Hepatitis Attributed to Terbinafine. Journal of Hepatology, 69, 1317-1325.
https://doi.org/10.1016/j.jhep.2018.08.004
|
[23]
|
Nicoletti, P., Werk, A.N., Sawle, A., Shen, Y., Urban, T.J., Coul-thard, S.A., et al. (2016) HLA-DRB1*16: 01-DQB1*05: 02 Is a Novel Genetic Risk Factor for Flupirtine-Induced Liver Injury. Pharmacogenetics and Genomics, 26, 218-224.
https://doi.org/10.1097/FPC.0000000000000209
|
[24]
|
Li, X., Jin, S., Fan, Y., Fan, X., Tang, Z., Cai, W., et al. (2019) Association of HLA-C*03:02 with Methimazole-Induced Liver Injury in Graves’ Disease Patients. Biomedicine & Pharmacotherapy, 117, Article ID: 109095.
https://doi.org/10.1016/j.biopha.2019.109095
|
[25]
|
Akmal, A. and Kung, J. (2014) Propylthiouracil, and Methi-mazole, and Carbimazole-Related Hepatotoxicity. Expert Opinion on Drug Safety, 13, 1397-1406. https://doi.org/10.1517/14740338.2014.953796
|
[26]
|
Clare, K., Miller, M. and Dillon, J. (2017) Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis? Current Hepatology Reports, 16, 258-264.
https://doi.org/10.1007/s11901-017-0363-9
|